Tezobell - Bortezomib

Tezobell - Bortezomib
Product Description

Composition: Bortezomib 3.5 mg

Indication: 
The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy. 

Packed in : Dry vial 3.5 mg

Read more Show less

PTCKD OTTO Pharmaceuticals

  • Country/Region:
    Indonesia
  • On CPHI since:
    2022
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
CMO/CDMO
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    Halal Ingredients; Price
  • Model
    Lyophilized Injection
  • Supplied from
    Indonesia
  • Measured In
    milligram
More specifications Fewer specifications
Sales Markets
Show more Show less

PTCKD OTTO Pharmaceuticals

  • Country/Region:
    Indonesia
  • On CPHI since:
    2022
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
CMO/CDMO
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile

More Products from PTCKD OTTO Pharmaceuticals (2)

  • Pemecine - Pemetrexed

    Product Pemecine - Pemetrexed

    Composition: Pemetrexed 100 mg & 500 mg

    Indication: The treatment of malignant pleural mesothelioma & non-small cell lung cancer

    Packed in : Dry vial 100 mg & 500 mg

  • Belloxa - Oxaliplatin

    Product Belloxa - Oxaliplatin

    Composition Oxaliplatin 50 mg &100 mg

    Indication
    Adjuvant treatment of stage III colon cancer (Duke stage C) after complete resection of initial tumor, treatment of metastatic colorectal cancer